ES2618353T3 - Clasificación de tumores y pronóstico del cáncer de mama - Google Patents

Clasificación de tumores y pronóstico del cáncer de mama Download PDF

Info

Publication number
ES2618353T3
ES2618353T3 ES08872935T ES08872935T ES2618353T3 ES 2618353 T3 ES2618353 T3 ES 2618353T3 ES 08872935 T ES08872935 T ES 08872935T ES 08872935 T ES08872935 T ES 08872935T ES 2618353 T3 ES2618353 T3 ES 2618353T3
Authority
ES
Spain
Prior art keywords
ratio
subject
index
classified
cut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08872935T
Other languages
English (en)
Spanish (es)
Inventor
Mark G. Erlander
Xiao-Jun Ma
Dennis Sgroi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheranostics Inc
Original Assignee
Biotheranostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheranostics Inc filed Critical Biotheranostics Inc
Application granted granted Critical
Publication of ES2618353T3 publication Critical patent/ES2618353T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES08872935T 2007-09-06 2008-09-06 Clasificación de tumores y pronóstico del cáncer de mama Active ES2618353T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97052907P 2007-09-06 2007-09-06
PCT/US2008/075528 WO2009108215A1 (en) 2007-09-06 2008-09-06 Tumor grading and cancer prognosis

Publications (1)

Publication Number Publication Date
ES2618353T3 true ES2618353T3 (es) 2017-06-21

Family

ID=40790735

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08872935T Active ES2618353T3 (es) 2007-09-06 2008-09-06 Clasificación de tumores y pronóstico del cáncer de mama

Country Status (7)

Country Link
US (3) US9447470B2 (enExample)
EP (1) EP2195467B1 (enExample)
JP (2) JP2010538609A (enExample)
CN (1) CN102395682B (enExample)
CA (1) CA2698569A1 (enExample)
ES (1) ES2618353T3 (enExample)
WO (1) WO2009108215A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
JP2008545431A (ja) * 2005-06-03 2008-12-18 アビアラデックス,インコーポレイティド 腫瘍および組織の同定
WO2010151731A1 (en) * 2009-06-26 2010-12-29 University Of Utah Research Foundation Materials and methods for the identification of drug-resistant cancers and treatment of same
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US20120270752A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with moments
US9470693B2 (en) 2012-05-18 2016-10-18 University Of North Dakota Method for quantifying proteins and isoforms thereof
MX369628B (es) * 2012-05-22 2019-11-14 Nanostring Technologies Inc Genes nano46 y metodos para predecir el resultado del cancer de mama.
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
US20150072021A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy
US20150203921A1 (en) 2013-09-11 2015-07-23 Biotheranostics, Inc. Predicting breast cancer recurrence
US10253369B2 (en) 2014-05-29 2019-04-09 Biotheranostics, Inc. Predicting likelihood of response to combination therapy
MX2018005867A (es) 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
CN107119055A (zh) * 2017-05-18 2017-09-01 南京中医药大学 分子标志物bub1b基因及其应用
CN110021433B (zh) * 2017-08-30 2023-11-17 中山大学 一种用于精准预测胃肠胰神经内分泌肿瘤患者预后的系统
MX2021001857A (es) * 2018-08-17 2021-10-13 Genentech Inc Star Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.
CN109706160A (zh) * 2019-02-22 2019-05-03 广西医科大学 重组人蛋白激酶Nek2蛋白表达和纯化方法
KR102405973B1 (ko) 2019-09-20 2022-06-07 고려대학교 산학협력단 유방암 초음파 영상과 유전자 정보를 이용한 유방암 치료법 선택을 위한 정보를 제공하는 방법
KR102508210B1 (ko) * 2020-10-16 2023-03-10 고려대학교 산학협력단 유방암 초음파 영상을 이용한 dna 유전자 정보를 제공하는 방법
CN115029437A (zh) * 2022-04-28 2022-09-09 深圳市陆为生物技术有限公司 检测样本中生物标志物的试剂在制备乳腺癌患者化疗响应评估产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
CA2350502C (en) 1998-11-13 2009-01-27 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US20030228575A1 (en) * 2001-01-31 2003-12-11 Yuk Ming Dennis Lo Combination of circulating epstein-barr virus (EBV) DNA in the serum or plasma of patients and a method to assess EBV subtypes for the prediction and detection of epstein-barr virus associated cancers
US20030064385A1 (en) * 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
CA2450379A1 (en) * 2001-06-10 2002-12-19 Irm Llc Molecular signatures of commonly fatal carcinomas
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
ES2787475T3 (es) * 2003-06-24 2020-10-16 Genomic Health Inc Predicción de probabilidad de recurrencia del cáncer
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005026735A2 (en) * 2003-09-18 2005-03-24 Genmab A/S Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
AU2004274973A1 (en) * 2003-09-19 2005-03-31 Aviaradx, Inc. Predicting breast cancer treatment outcome
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
US7498693B2 (en) 2004-02-18 2009-03-03 Diversified Technologies, Inc. More compact and higher reliability power source system
WO2006119593A1 (en) * 2005-05-13 2006-11-16 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
JP2008545431A (ja) * 2005-06-03 2008-12-18 アビアラデックス,インコーポレイティド 腫瘍および組織の同定

Also Published As

Publication number Publication date
JP2015057055A (ja) 2015-03-26
US20110136680A1 (en) 2011-06-09
US12492432B2 (en) 2025-12-09
US11021754B2 (en) 2021-06-01
WO2009108215A1 (en) 2009-09-03
EP2195467B1 (en) 2016-12-14
US20210371934A1 (en) 2021-12-02
CA2698569A1 (en) 2009-09-03
EP2195467A1 (en) 2010-06-16
CN102395682A (zh) 2012-03-28
CN102395682B (zh) 2015-09-30
US9447470B2 (en) 2016-09-20
US20180291461A1 (en) 2018-10-11
JP2010538609A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
ES2618353T3 (es) Clasificación de tumores y pronóstico del cáncer de mama
Thennavan et al. Molecular analysis of TCGA breast cancer histologic types
Grover et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research
Chen et al. Histologic grade as prognostic indicator for mucoepidermoid carcinoma: a population‐level analysis of 2400 patients
Budczies et al. Classical pathology and mutational load of breast cancer–integration of two worlds
Zhao et al. Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA
Bradford et al. Molecular markers of prostate cancer
Rodríguez-Suárez et al. Urine as a source for clinical proteome analysis: from discovery to clinical application
Passoni et al. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis
MX374827B (es) Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer.
EA035451B9 (ru) Способ диагностики рака с использованием геномного секвенирования
NZ719474A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB2427468A (en) Devices and methods for enrichment and alteration of circulating tumour cells and other particles
Xu et al. The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells
Qi et al. Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
Granit et al. Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition
Jiang et al. Overexpression of LncRNA GHET1 predicts an unfavourable survival and clinical parameters of patients in various cancers
Zhang et al. Identification of a recurrence signature and validation of cell infiltration level of thyroid cancer microenvironment
Ball et al. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer
CN107561280A (zh) 一种预测乳腺癌复发的试剂盒
WO2018093236A3 (ko) 유방암 환자의 예후 예측 방법
Ha et al. Differential expression of forkhead box M1 and its downstream cyclin‐dependent kinase inhibitors p27kip1 and p21waf1/cip1 in the diagnosis of pulmonary neuroendocrine tumours
García et al. 18F-FDG PET/CT as predictor of tumor biology and prognosis in epithelial ovarian carcinoma
Kreppel et al. Prognostic quality of the Union Internationale Contre le Cancer/American Joint Committee on Cancer TNM classification, for cancer of the maxillary sinus